Aptuit, Axxam Enter Strategic Services Alliance

Aptuit LLC and Axxam SpA have entered a strategic alliance to provide integrated drug discovery and development services from gene to candidates and beyond. Additionally, the companies’ began their first significant joint integrated project with a large pharma company. 
 
Aptuit provides drug discovery and development services for early discovery to mid-phase and Axxam is a discovery company with expertise in target biology and a broad range of early phase discovery services.
 
Jonathan Goldman, chief executive officer, Aptuit said, “We serve biopharmaceutical companies in the discovery of small molecules in a broad range of therapeutic areas. Our alliance with Axxam is part of our growth strategy. This best-in-class partnership broadens Aptuit’s scientific excellence in advanced integrated discovery by leveraging Axxam’s capabilities in early discovery. In particular we are excited to enhance our hit identification, validation, and expansion services, by allowing seamless and very high quality delivery of an asset from target to candidate nomination.” 
 
Stefan Lohmer, co-founder and chief executive officer of Axxam SpA, added, “We are very pleased to announce the strategic alliance with Aptuit. Our companies share a common culture of scientific excellence and quality. This alliance will allow some of our customers to leverage our deep expertise in target biology, assay development and High Throughput Screening even further. The complementary and comprehensive skillsets of our two companies include all the scientific disciplines necessary to translate a promising target into a preclinical candidate.”